H-Val-Pro-Pro-OH TFA

Cas No.:	2828433-08-3
Chemical Name:	H-Val-Pro-Pro-OH TFA
Synonyms:	(S)-1-((S)-1-((S)-2-Amino-3-methylbutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxylic acid trifluoroacetate;H-Val-Pro-Pro-OH TFA;CS-0077836;G16510;VPP TFA;2828433-08-3;HY-114161A;H-Val-Pro-Pro-OH (TFA);(2S)-1-[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid;2,2,2-trifluoroacetic acid;MS-27486
SMILES:	C(F)(F)(F)C(=O)O.C(N1CCC[C@H]1C(=O)O)([C@@H]1CCCN1C(=O)[C@@H](N)C(C)C)=O
Formula:	C₁₇H₂₆F₃N₃O₆
M.Wt:	425.400055408478
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

In Vitro H-Val-Pro-Pro-OH (TFA), a proline peptides derivative, could inhibit Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM. H-Val-Pro-Pro-OH (TFA) could enhance insulin sensitivity and prevent insulin resistance in 3T3-F442A pre-adipocytes. H-Val-Pro-Pro-OH (TFA) also has anti-hypertensive and anti-inflammatory functions. H-Val-Pro-Pro-OH (TFA) further enhances the expression of glucose transporter 4 (GLUT4) in adipocytes and restores glucose uptake in TNF-treated adipocytes.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC12255	MLN-4760	MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).
DC12262	H-Val-Pro-Pro-OH TFA	H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
DC9325	Cilazapril (monohydrate)	Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
DC72664	Bradykinin potentiator C	Bradykinin potentiator C is a potent angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 7.1 μM for rabbit lung ACE. Bradykinin potentiator C is a postulated prototype of functional peptide.
DC72369	RXPA 380	RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM.
DC72051	Temocapril	Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
DC71540	Spiraprilat	Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF).
DC71171	Moexipril	Moexipril is an orally active and potent angiotensin-converting enzyme (ACE) inhibitor. Moexipril can readily penetrate lipid membranes and thus target plasma and tissue ACE. Moexipril may improve endothelial dysfunction and exert neuroprotective effects. Moexipril can used for cardiovascular disease research.
DC71086	Moveltipril	Moveltipril is a potent angiotensin converting enzyme (ACE) inhibitor.
DC49726	AD013	AD013 is a dual inhibitor of cACE/NEP. AD013 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD013 has the potential for providing the potent antihypertensive and cardioprotective benefits.